Home › Companies › Denali Therapeutics Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Denali Therapeutics Inc.’s Form 8-K, filed June 4, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 3, 2026: 5 items on Denali Therapeutics Inc.’s Form 8-K, filed June 4, 2026: 3 elected · 2 approved.
Significant dissent: 2 directors (39.1%, 26.5% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Denali Therapeutics Inc. in the interactive database Compare manager voting policies
These tallies are Denali Therapeutics Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jennifer Cook | 75,998,259 | -- | -- | 48,847,029 | 13,140,839 | 61% | Elected | — |
| Elect Director: David Schenkein, M.D. | 91,814,688 | -- | -- | 33,030,600 | 13,140,839 | 74% | Elected | — |
| Elect Director: Ryan Watts, Ph.D. | 121,220,572 | -- | -- | 3,624,716 | 13,140,839 | 97% | Elected | — |
| 2. Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 137,516,267 | 420,305 | 49,555 | -- | -- | 99.7% | Approved | — |
| 3. Advisory Vote to Approve Executive Compensation | 117,038,745 | 7,088,810 | 717,733 | -- | 13,140,839 | 94% | Approved | — |
Source: Denali Therapeutics Inc., Form 8-K, filed with the SEC on June 4, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
279 asset managers disclosed a vote on at least one Denali Therapeutics Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTORS: David Schenkein, M.D.
Denali Therapeutics Inc.’s own tally for this item (“Elect Director: David Schenkein, M.D.”): 91,814,688 for, 33,030,600 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class III director, to hold office until the Company's 2029 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 71 asset managers below reported 37,281,142 for, 10,478,120 withheld, 311,495 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 15,259,197 | 0 | 87 | 0 | For |
| T. Rowe Price | 1,705,163 | 0 | 0 | 5,207,668 | Mixed |
| Fidelity | 5,767,405 | 0 | 0 | 0 | For |
| BlackRock | 5,584,177 | 0 | 0 | 0 | For |
| Capital Group | 2,687,684 | 0 | 0 | 0 | For |
| State Street | 2,401,485 | 0 | 0 | 2,712 | For |
| Charles Schwab | 1,207,165 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 895,718 | Withhold |
| Principal | 0 | 0 | 0 | 792,720 | Withhold |
| Dimensional | 0 | 0 | 0 | 752,453 | Withhold |
| Goldman Sachs | 694,627 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 660,212 | Withhold |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 608,609 | Withhold |
| Equitable | 212,430 | 0 | 0 | 333,761 | Mixed |
| TIAA | 278,450 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 230,704 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 178,812 | 0 | Abstain |
| BNY Mellon | 156,361 | 0 | 0 | 5,106 | For |
| Lincoln Financial | 101,423 | 0 | 0 | 51,347 | Mixed |
| JPMorgan | 138,960 | 0 | 0 | 0 | For |
| Segall Bryant & Hamill Trust | 0 | 0 | 0 | 138,028 | Withhold |
| Invesco | 121,891 | 0 | 0 | 0 | For |
| Brighthouse | 70,898 | 0 | 0 | 45,013 | Mixed |
| OPTIMUM FUND TRUST | 0 | 0 | 0 | 114,524 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 110,155 | Withhold |
Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
61% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTORS: Jennifer Cook
Denali Therapeutics Inc.’s own tally for this item (“Elect Director: Jennifer Cook”): 75,998,259 for, 48,847,029 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class III director, to hold office until the Company's 2029 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”
Support: 61% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 71 asset managers below reported 28,911,364 for, 13,528,808 withheld, 5,630,585 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 15,251,294 | 0 | 105 | 7,885 | For |
| T. Rowe Price | 1,705,163 | 0 | 0 | 5,207,668 | Mixed |
| Fidelity | 5,705,270 | 0 | 0 | 62,135 | For |
| BlackRock | 558,168 | 0 | 5,026,009 | 0 | Mixed |
| Capital Group | 2,687,684 | 0 | 0 | 0 | For |
| State Street | 4,788 | 0 | 0 | 2,399,409 | Withhold |
| Charles Schwab | 1,207,165 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 895,718 | Withhold |
| Principal | 0 | 0 | 0 | 792,720 | Withhold |
| Dimensional | 0 | 0 | 0 | 752,453 | Withhold |
| Goldman Sachs | 694,627 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 660,212 | Withhold |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 608,609 | Withhold |
| Equitable | 8,698 | 0 | 0 | 537,493 | Withhold |
| TIAA | 278,450 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 230,704 | 0 | Abstain |
| Jackson National | 0 | 0 | 178,812 | 0 | Abstain |
| BNY Mellon | 156,361 | 0 | 0 | 5,106 | For |
| Lincoln Financial | 12,023 | 0 | 0 | 140,747 | Mixed |
| JPMorgan | 138,960 | 0 | 0 | 0 | For |
| Segall Bryant & Hamill Trust | 0 | 0 | 0 | 138,028 | Withhold |
| Invesco | 121,891 | 0 | 0 | 0 | For |
| Brighthouse | 70,898 | 0 | 0 | 45,013 | Mixed |
| OPTIMUM FUND TRUST | 0 | 0 | 0 | 114,524 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 110,155 | Withhold |
Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTORS: Ryan Watts, Ph.D.
Denali Therapeutics Inc.’s own tally for this item (“Elect Director: Ryan Watts, Ph.D.”): 121,220,572 for, 3,624,716 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class III director, to hold office until the Company's 2029 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 71 asset managers below reported 47,151,247 for, 844,207 withheld, 75,304 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 15,259,274 | 0 | 10 | 0 | For |
| T. Rowe Price | 6,912,831 | 0 | 0 | 0 | For |
| Fidelity | 5,767,405 | 0 | 0 | 0 | For |
| BlackRock | 5,584,177 | 0 | 0 | 0 | For |
| Capital Group | 2,687,684 | 0 | 0 | 0 | For |
| State Street | 2,404,173 | 0 | 0 | 24 | For |
| Charles Schwab | 1,207,165 | 0 | 0 | 0 | For |
| AllianceBernstein | 895,718 | 0 | 0 | 0 | For |
| Principal | 792,720 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 752,453 | Withhold |
| Goldman Sachs | 694,627 | 0 | 0 | 0 | For |
| American Century | 660,212 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 608,609 | 0 | 0 | 0 | For |
| Equitable | 546,191 | 0 | 0 | 0 | For |
| TIAA | 278,450 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 230,704 | 0 | 0 | 0 | For |
| Jackson National | 147,258 | 0 | 31,554 | 0 | Mixed |
| BNY Mellon | 161,467 | 0 | 0 | 0 | For |
| Lincoln Financial | 145,338 | 0 | 0 | 7,432 | For |
| JPMorgan | 138,960 | 0 | 0 | 0 | For |
| Segall Bryant & Hamill Trust | 138,028 | 0 | 0 | 0 | For |
| Invesco | 121,891 | 0 | 0 | 0 | For |
| Brighthouse | 115,911 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 114,524 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 110,155 | 0 | 0 | 0 | For |
Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
94% Approved · of votes cast
Prior year: 91.0% for (June 3, 2025 meeting) ▲ 3.3 pts
Description as filed by funds: To approve, on an advisory basis, executive compensation.
Denali Therapeutics Inc.’s own tally for this item (“3. Advisory Vote to Approve Executive Compensation”): 117,038,745 for, 7,088,810 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Advisory Vote to Approve Executive Compensation The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 15,259,271 | 10 | 2 | 0 | For |
| T. Rowe Price | 6,912,831 | 0 | 0 | 0 | For |
| Fidelity | 5,767,405 | 0 | 0 | 0 | For |
| BlackRock | 5,584,177 | 0 | 0 | 0 | For |
| Capital Group | 0 | 2,687,684 | 0 | 0 | Against |
| State Street | 2,404,197 | 0 | 0 | 0 | For |
| Charles Schwab | 1,207,165 | 0 | 0 | 0 | For |
| AllianceBernstein | 895,718 | 0 | 0 | 0 | For |
| Principal | 792,720 | 0 | 0 | 0 | For |
| Dimensional | 752,453 | 0 | 0 | 0 | For |
| Goldman Sachs | 694,627 | 0 | 0 | 0 | For |
| American Century | 0 | 660,212 | 0 | 0 | Against |
| AB DISCOVERY GROWTH FUND, INC. | 608,609 | 0 | 0 | 0 | For |
| Equitable | 546,191 | 0 | 0 | 0 | For |
| TIAA | 278,450 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 230,704 | 0 | 0 | 0 | For |
| Jackson National | 178,812 | 0 | 0 | 0 | For |
| BNY Mellon | 161,467 | 0 | 0 | 0 | For |
| Lincoln Financial | 152,770 | 0 | 0 | 0 | For |
| JPMorgan | 138,960 | 0 | 0 | 0 | For |
| Segall Bryant & Hamill Trust | 138,028 | 0 | 0 | 0 | For |
| Invesco | 121,891 | 0 | 0 | 0 | For |
| Brighthouse | 115,911 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 114,524 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 110,155 | 0 | 0 | 0 | For |
Fund voting reports, all 71 managers: 44,679,372 for, 3,347,906 against, 43,827 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 11,253,989 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD & CO LTD | 8,667,248 | 0 | 0 | 0 | For |
| State Street | 5,290,025 | 0 | 0 | 0 | For |
| BlackRock | 4,842,996 | 164 | 0 | 0 | For |
| Fidelity | 4,531,650 | 0 | 0 | 0 | For |
| BAKER BROS. ADVISORS LP | 3,731,695 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 3,731,131 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD OVERSEAS LTD | 3,040,954 | 0 | 0 | 0 | For |
| AllianceBernstein | 2,745,634 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 0 | 2,687,684 | 0 | 0 | Against |
| PICTET ASSET MANAGEMENT SA | 2,402,881 | 0 | 0 | 0 | For |
| UBS | 0 | 1,895,335 | 0 | 0 | Against |
| Lynx1 Capital Management LP | 1,880,303 | 0 | 0 | 0 | For |
| Aberdeen | 1,854,446 | 0 | 0 | 0 | For |
| Goldman Sachs | 1,638,507 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 1,491,431 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 1,396,513 | 0 | 0 | 0 | For |
| Charles Schwab | 1,220,289 | 0 | 0 | 0 | For |
| Foresite Capital Management VI LLC | 1,209,971 | 0 | 0 | 0 | For |
| Vanguard | 1,187,170 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 1,099,845 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 982,036 | 0 | 0 | 0 | For |
| Northern Trust | 956,150 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 846,762 | 0 | 0 | 0 | For |
| Artisan | 784,215 | 0 | 0 | 0 | For |
Institutional-manager reports, all 222 managers: 74,897,630 for, 6,063,611 against, 81 abstained, 3,322 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.7% Approved · of votes cast
Prior year: 99.8% for (June 3, 2025 meeting) ▼ 0.1 pts
Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2026.
Denali Therapeutics Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, ”): 137,516,267 for, 420,305 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting:”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 72 asset managers below reported 48,009,137 for, 18,153 against, 43,825 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 15,259,283 | 1 | 0 | 0 | For |
| T. Rowe Price | 6,912,831 | 0 | 0 | 0 | For |
| Fidelity | 5,767,405 | 0 | 0 | 0 | For |
| BlackRock | 5,584,177 | 0 | 0 | 0 | For |
| Capital Group | 2,687,684 | 0 | 0 | 0 | For |
| State Street | 2,404,103 | 94 | 0 | 0 | For |
| Charles Schwab | 1,207,165 | 0 | 0 | 0 | For |
| AllianceBernstein | 895,718 | 0 | 0 | 0 | For |
| Principal | 792,720 | 0 | 0 | 0 | For |
| Dimensional | 752,453 | 0 | 0 | 0 | For |
| Goldman Sachs | 694,627 | 0 | 0 | 0 | For |
| American Century | 660,212 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 608,609 | 0 | 0 | 0 | For |
| Equitable | 546,191 | 0 | 0 | 0 | For |
| TIAA | 278,450 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 230,704 | 0 | 0 | 0 | For |
| Jackson National | 178,812 | 0 | 0 | 0 | For |
| BNY Mellon | 161,467 | 0 | 0 | 0 | For |
| Lincoln Financial | 152,770 | 0 | 0 | 0 | For |
| JPMorgan | 138,960 | 0 | 0 | 0 | For |
| Segall Bryant & Hamill Trust | 138,028 | 0 | 0 | 0 | For |
| Invesco | 121,891 | 0 | 0 | 0 | For |
| Brighthouse | 115,911 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 114,524 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 110,155 | 0 | 0 | 0 | For |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 158,656,318 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 9.62% |
| 2 | T. Rowe Price | 4.36% |
| 3 | Fidelity | 3.64% |
| 4 | BlackRock | 3.52% |
| 5 | Capital Group | 1.69% |
| 6 | State Street | 1.52% |
| 7 | Charles Schwab | 0.76% |
| 8 | AllianceBernstein | 0.56% |
| 9 | Principal | 0.50% |
| 10 | Dimensional | 0.47% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | T. Rowe Price | 7.09% |
| 2 | BAILLIE GIFFORD & CO LTD | 5.46% |
| 3 | State Street | 3.33% |
| 4 | BlackRock | 3.05% |
| 5 | Fidelity | 2.86% |
| 6 | BAKER BROS. ADVISORS LP | 2.35% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 2.35% |
| 8 | BAILLIE GIFFORD OVERSEAS LTD | 1.92% |
| 9 | AllianceBernstein | 1.73% |
| 10 | Capital Research Global Investors | 1.69% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Vanguard Group | 13,057,890 | 8.23% | Form 13F, quarter ended March 31, 2026 |
| BlackRock | 13,034,434 | 8.22% | Form 13F, quarter ended March 31, 2026 |
| BAILLIE GIFFORD & CO | 11,960,230 | 7.54% | Schedule 13G, filed August 4, 2026 |
| FMR LLC | 8,536,392 | 5.38% | Proxy statement (DEF 14A), table as of March 31, 2026 |
| Julian C. Baker | 8,136,208 | 5.13% | Proxy statement (DEF 14A), table as of March 31, 2026 |
| State Street | 6,272,001 | 3.95% | Form 13F, quarter ended March 31, 2026 |
| FMR (Fidelity) | 4,575,374 | 2.88% | Form 13F, quarter ended March 31, 2026 |
| Goldman Sachs | 4,407,255 | 2.78% | Form 13F, quarter ended March 31, 2026 |
| Ryan J. Watts, Ph.D. | 4,258,400 | 2.68% | Proxy statement (DEF 14A), table as of March 31, 2026 |
| Geode Capital | 3,727,114 | 2.35% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 158,656,318 shares outstanding, as reported by Denali Therapeutics Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Denali Therapeutics Inc.'s shareholder meeting held June 3, 2026, in the 2025-2026 proxy season, 279 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,656 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, executive compensation. — Denali Therapeutics Inc.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Denali Therapeutics Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Denali Therapeutics Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Denali Therapeutics Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Denali Therapeutics (DNLI) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/denali-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.